GlassScriptPhysician profile
Robert M Levenson
NPI 1326080334
$2,489.86
in general payments reported to CMS, 2019-2025
19 companies · $203 in 2025
The $203 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,541 · 2021: $54.77 · 2022: $36.23 · 2023: $352 · 2024: $303 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $858.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $858.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $1,148.71 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $349.00 | 2019-2025 | Lynparza, Enhertu |
| Glaxosmithkline, LLC. | $270.83 | 2024 | Zejula |
| E.R. Squibb & Sons, L.L.C. | $141.68 | 2019-2023 | Opdivo |
| Emd Serono, INC. | $125.00 | 2023 | Bavencio |
| Janssen Biotech, INC. | $102.89 | 2019-2025 | Rybrevant, Carvykti |
| Amgen INC. | $63.43 | 2019 | |
| Lilly USA, LLC | $49.19 | 2019-2023 | Retevmo, Jaypirca |
| Celgene Corporation | $38.14 | 2019 | |
| Novartis Pharmaceuticals Corporation | $36.23 | 2019-2022 | |
| Pfizer INC. | $30.17 | 2019 | |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.62 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.54 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $17.22 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $14.54 | 2023 | Phesgo, Perjeta |
| Daiichi Sankyo INC. | $14.00 | 2025 | Enhertu |
| Clovis Oncology, INC. | $13.83 | 2019 | |
| Astellas Pharma US INC | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Levenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.